<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643822</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0164-B</org_study_id>
    <nct_id>NCT03643822</nct_id>
  </id_info>
  <brief_title>Adjuncts for Adductor Block: Dexamethasone,Dexmedetomidine, or Combination to Reduce Pain</brief_title>
  <acronym>AADDCToR</acronym>
  <official_title>Adjuncts for Adductor Block: Dexamethasone,Dexmedetomidine, or Combination to Reduce Pain. A Randomized Controlled Comparison of the Analgesic Effects Following ACL Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women's College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women's College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this multi-centered study is to evaluate the effects of two distinct Adductor
      Canal Block (ACB) adjuncts, dexamethasone and dexmedetomidine, and their combination, on
      postoperative analgesia in patients undergoing Anterior Cruciate Ligament (ACL) Repair.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anterior cruciate ligament repair (ACLR) is a surgical procedure of the knee associated with
      moderate to severe postoperative pain lasting beyond 24 hours following surgery. Provision of
      adequate postoperative analgesia is a prerequisite for performing this procedure on
      outpatient basis. By virtue of their analgesic effects, peripheral nerve blocks (PNBs), such
      as adductor canal block (ACB), have thus become part of the care standard for this surgical
      procedure.

      Though ACB provides effective pain relief, the duration of analgesia associated with this
      block is limited to eight hours postoperatively. As a result, patients having outpatient ACLR
      may experience severe pain following discharge, require additional opioid analgesics to
      control their pain, and even visit the emergency department for acute pain management.
      Consequently, perioperative care for the young outpatient population undergoing this
      procedure is an area where improvement is needed.

      Mixing adjuncts with local anesthetics can prolong the duration of analgesia of PNBs; both
      dexmedetomidine and dexamethasone have been shown to effectively extend the duration of PNB
      analgesia by 60% and 80% hours, respectively. The use of dexamethasone is wide spread, and
      dexmedetomidine is progressively gaining popularity.

      At Toronto Western Hospital, the use of adjuncts is left to the discretion of the
      anesthesiologists administering PNB; and dexamethasone is occasionally used to prolong block
      duration. The alternative approach to prolonging block duration is using ambulatory ACB
      catheters, but this is an expensive option that is applicable to select patients, and it is
      not available at the TWH.

      Importantly, these adjuncts seem to exert their effect through independent mechanisms; thus
      there may be an advantage to combining adjuncts together. Further prolongation of the
      duration of analgesia is desirable, as the prolongation of block duration associated with
      each of these two adjuncts, alone, falls short of the duration of worst postoperative pain
      following ACLR. Consequently, the investigators aimed to explore whether the combination of
      these two adjuncts offers an incremental benefit over either of them alone, by examining
      their potential additive or synergistic effect.

      This randomized controlled trial compares the effect of using perineural dexamethasone,
      dexmedetomidine, and their combination to Control on the duration of postoperative analgesia
      in patients having ambulatory ACLR with ACB.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>There will be prospective,randomized,controlled,parallel group,factorial,1:1:1:1 allocation,operator,patient and assessor blinded clinical trial.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patients who give written informed consent will be randomly assigned on the day of surgery to either of the four study groups using a computer-generated block randomization schedule in blocks of varying sizes. Group allocation will not be disclosed to the anesthesiologist performing the ACB. An anesthesia assistant will receive an opaque envelope containing the result of randomization, and will prepare the block study solution in identical syringes. The patient receiving ACB will also be blinded to the study solution injected. Furthermore, outcome assessment will be performed by a blinded research assistant.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Oral opioid consumption</measure>
    <time_frame>time of the block to 24 hours after</time_frame>
    <description>Cumulative 24 hour oral morphine equivalent consumption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-operative opioid consumption</measure>
    <time_frame>Duration of surgery: From start of surgery (defined as anesthesia start) to end of surgery (defined as anesthesia end)</time_frame>
    <description>Cumulative intra-operative opioid consumption in morphine equivalent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU opioid consumption</measure>
    <time_frame>From time of arrival (hh:mm) in PACU to time of PACU discharge (hh:mm) assessed up to 24 hours</time_frame>
    <description>Cumulative oral morphine equivalent consumption during time stayed in PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first analgesic request in PACU</measure>
    <time_frame>From time of arrival in PACU (hh:mm) up to time of PACU discharge (hh:mm) assessed in minutes up to 24 hours ((e.g. patient arrives in PACU 12:00 then patient is given first pain medication in PACU at 12:30; Time to first analgesic request = 30 min)</time_frame>
    <description>The time (hh:mm) first pain medication given in PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PACU discharge</measure>
    <time_frame>From time of arrival (hh:mm) in PACU to time discharged (hh:mm) from PACU assessed in minutes (e.g. patient arrives in PACU 12:00 then patient discharged from PACU 12:30; Time to PACU discharge = 30 min)</time_frame>
    <description>how fast patient recovered and discharged from PACU (measured in minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale-Pain scores - minimum score = 0 and maximum score = 10</measure>
    <time_frame>discharge from hospital to 2 days after surgery</time_frame>
    <description>pain scores at 0, 2, 4, 6, 12, 24, 36, and 48 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>discharge from hospital to 2 days after surgery</time_frame>
    <description>analgesic consumption at 6, 12, 24, 36, and 48 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of block-related complications</measure>
    <time_frame>one week post operatively</time_frame>
    <description>adverse symptoms related to the block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of opioid-related side effects</measure>
    <time_frame>two week post operatively</time_frame>
    <description>adverse symptoms related to oral pain medication consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery-15 (QoR15) (0-10, where 0 = none of the time [poor] and 10 = all of the time [excellent]</measure>
    <time_frame>discharge from hospital to 24 hours after surgery</time_frame>
    <description>measured using the Quality of recovery-15 at 12 and 24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge</measure>
    <time_frame>From time of end of surgery [(hh:mm) defined as anesthesia end] up to time of hospital discharge (hh:mm) assessed in minutes up to 24 hours (e.g. surgery ends 12:00, then patient discharged from the hospital at 13:00; Time to hospital discharge = 60min</time_frame>
    <description>Measures of recovery (how many minutes from end of surgery to discharge from hospital)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first analgesic request at home (after discharge)</measure>
    <time_frame>discharge from hospital to 24 hours after surgery</time_frame>
    <description>first time(hh:mm) patient took an oral pain medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale-Satisfaction scores - where 0 = not satisfied and 10 = very satisfied</measure>
    <time_frame>evaluated at 12 and 24 hours post-surgery</time_frame>
    <description>A visual analogue scale used to measure how satisfied the study participant is with the pain relief received for shoulder surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of nerve block complications</measure>
    <time_frame>time from block onset to 2 days,2 weeks after surgery</time_frame>
    <description>adverse symptoms related to the block</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>ACL Injury</condition>
  <arm_group>
    <arm_group_label>Dexamethasone vs. Control comparison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Freezing + dexamethasone(4mg)+1 ml of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine vs. Control comparison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Freezing + dexmedetomidine(50ug) + 1.5 ml of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone and Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Freezing+dexamethasone(4mg)+dexmedetomidine(50ug) + 0.5 ml of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group-Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Freezing + 2ml saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4mg</intervention_name>
    <description>To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.</description>
    <arm_group_label>Dexamethasone and Dexmedetomidine</arm_group_label>
    <arm_group_label>Dexamethasone vs. Control comparison</arm_group_label>
    <other_name>Preservative free Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.</description>
    <arm_group_label>Dexamethasone and Dexmedetomidine</arm_group_label>
    <arm_group_label>Dexmedetomidine vs. Control comparison</arm_group_label>
    <other_name>Dexmedetomidine Hydrochloride 0.5 MG/ML</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Control/Placebo intervention</description>
    <arm_group_label>Control Group-Placebo</arm_group_label>
    <arm_group_label>Dexamethasone and Dexmedetomidine</arm_group_label>
    <arm_group_label>Dexamethasone vs. Control comparison</arm_group_label>
    <arm_group_label>Dexmedetomidine vs. Control comparison</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English Speaking

          -  ASA 1-3 patients

          -  BMI &lt;38

        Exclusion Criteria:

          -  Refusal or inability to provide informed consent

          -  Any contraindication to regional anesthesia including coagulopathy or bleeding
             diathesis, allergy to local anesthetics, infection, nerve injury or malignancy at the
             site of the block

          -  History of alcohol/drug dependence

          -  History of long term opioid intake or chronic pain disorder

          -  History of preexisting neuropathy in the operative leg

          -  History of significant psychiatric conditions that may affect patient assessment

          -  Inability to understand the informed consent and demands of the study

          -  Allergy to any of the components of the multimodal analgesic regimen

          -  Revision of ACL repair

          -  Diabetes

          -  Significant bradycardia (baseline heart rate â‰¤ 40 beats per minute)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Brull, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Didem Bozak</last_name>
    <phone>416-323-6008</phone>
    <email>didem.bozak@wchospital.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Women's College Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Brull, MD</last_name>
      <phone>416-323-6400</phone>
      <phone_ext>4239</phone_ext>
      <email>richard.brull@wchospital.ca</email>
    </contact>
    <contact_backup>
      <last_name>Didem Bozak</last_name>
      <phone>416-323-6400</phone>
      <phone_ext>6008</phone_ext>
      <email>didem.bozak@wchospital.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACB adjuncts</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>post operative analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anterior Cruciate Ligament Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

